Printer Friendly

Oncolytics Biotech Inc.

Elsewhere, Oncolytics Biotech Inc. (Nasdaq) jumped 23 cents, or 14%, to $1.86. The company said it had completed an initial production run of Reolysin, a potential cancer therapeutic. The treatment is based on a human reovirus and is designed to target and destroy cancer cells, either alone or combined with radiation or chemotherapy. "Reolysin is a cancer therapeutic but it is different than all the other drugs that are out there and being developed," said Reni Benjamin, an analyst at Rodman & Renshaw. "This is still a product being evaluated in clinical trials but there is some potential for this product as a therapy," Benjamin said. "With the clinical results reported to date and the expected initiation of our pivotal program this year, keeping pace with the manufacturing process is critical," said Dr. Matt Coffey, chief operating officer of Oncolytics. Oncolytics' clinical program includes a variety of Phase 1 and Phase 2 human trials using Reolysin.
COPYRIGHT 2009 MedContent Media, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Medical Stock Spotlight; production run of Reolysin
Publication:MondayMorning
Article Type:Brief article
Date:Aug 3, 2009
Words:156
Previous Article:WellCare Health Plans Inc.
Next Article:Agilent to buy Varian.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters